301 related articles for article (PubMed ID: 32081560)
61. Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance.
Zhao F; Vesprini D; Liu RSC; Olkhov-Mitsel E; Klotz LH; Loblaw A; Liu SK; Bapat B
Urol Oncol; 2019 May; 37(5):297.e9-297.e17. PubMed ID: 30777394
[TBL] [Abstract][Full Text] [Related]
62. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
63. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer.
Shariat SF; Casella R; Khoddami SM; Hernandez G; Sulser T; Gasser TC; Lerner SP
J Urol; 2004 Feb; 171(2 Pt 1):626-30. PubMed ID: 14713774
[TBL] [Abstract][Full Text] [Related]
64. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer.
Yafi FA; Brimo F; Steinberg J; Aprikian AG; Tanguay S; Kassouf W
Urol Oncol; 2015 Feb; 33(2):66.e25-31. PubMed ID: 25037483
[TBL] [Abstract][Full Text] [Related]
65. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
[TBL] [Abstract][Full Text] [Related]
66. Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up.
Cancel-Tassin G; Roupret M; Pinar U; Gaffory C; Vanie F; Ondet V; Compérat E; Cussenot O
World J Urol; 2021 Sep; 39(9):3329-3335. PubMed ID: 33770241
[TBL] [Abstract][Full Text] [Related]
67. Cell-free microRNA expression signatures in urine serve as novel noninvasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
Du L; Jiang X; Duan W; Wang R; Wang L; Zheng G; Yan K; Wang L; Li J; Zhang X; Pan H; Yang Y; Wang C
Oncotarget; 2017 Jun; 8(25):40832-40842. PubMed ID: 28388561
[TBL] [Abstract][Full Text] [Related]
68. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.
Kandimalla R; Masius R; Beukers W; Bangma CH; Orntoft TF; Dyrskjot L; van Leeuwen N; Lingsma H; van Tilborg AA; Zwarthoff EC
Clin Cancer Res; 2013 Sep; 19(17):4760-9. PubMed ID: 23842048
[TBL] [Abstract][Full Text] [Related]
69. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments.
Chung W; Bondaruk J; Jelinek J; Lotan Y; Liang S; Czerniak B; Issa JP
Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1483-91. PubMed ID: 21586619
[TBL] [Abstract][Full Text] [Related]
70. Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria.
Xu Y; Kim YH; Jeong P; Piao XM; Byun YJ; Kang HW; Kim WT; Lee JY; Kim IY; Moon SK; Choi YH; Yun SJ; Kim WJ
Urol Oncol; 2019 Jan; 37(1):86-96. PubMed ID: 30446454
[TBL] [Abstract][Full Text] [Related]
71. Clinical performance and utility of a DNA methylation urine test for bladder cancer.
Abern MR; Owusu R; Inman BA
Urol Oncol; 2014 Jan; 32(1):51.e21-6. PubMed ID: 24360662
[TBL] [Abstract][Full Text] [Related]
72. High Detection Rate for Non-Muscle-Invasive Bladder Cancer Using an Approved DNA Methylation Signature Test.
Steinbach D; Kaufmann M; Hippe J; Gajda M; Grimm MO
Clin Genitourin Cancer; 2020 Jun; 18(3):210-221. PubMed ID: 32139301
[TBL] [Abstract][Full Text] [Related]
73. Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test.
Zhang S; Wang Y; Bondaruk J; Majewski T; Yao H; Lee S; Lee JG; Cogdell D; Lotan Y; Dinney C; Wei P; Baggerly K; Czerniak B
Eur Urol Focus; 2019 Jul; 5(4):664-675. PubMed ID: 29428551
[TBL] [Abstract][Full Text] [Related]
74. A multi-analyte assay for the non-invasive detection of bladder cancer.
Goodison S; Chang M; Dai Y; Urquidi V; Rosser CJ
PLoS One; 2012; 7(10):e47469. PubMed ID: 23094052
[TBL] [Abstract][Full Text] [Related]
75. Individual risk assessment in bladder cancer patients based on a multi-marker panel.
Todenhöfer T; Hennenlotter J; Aufderklamm S; Kühs U; Gakis G; Germann M; Stenzl A; Schwentner C
J Cancer Res Clin Oncol; 2013 Jan; 139(1):49-56. PubMed ID: 22893018
[TBL] [Abstract][Full Text] [Related]
76. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.
Zuiverloon TC; van der Aa MN; van der Kwast TH; Steyerberg EW; Lingsma HF; Bangma CH; Zwarthoff EC
Clin Cancer Res; 2010 Jun; 16(11):3011-8. PubMed ID: 20404005
[TBL] [Abstract][Full Text] [Related]
77. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel.
Dulaimi E; Uzzo RG; Greenberg RE; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Mar; 10(6):1887-93. PubMed ID: 15041703
[TBL] [Abstract][Full Text] [Related]
78. Cell-free lncRNA expression signatures in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
Du L; Duan W; Jiang X; Zhao L; Li J; Wang R; Yan S; Xie Y; Yan K; Wang Q; Wang L; Yang Y; Wang C
J Cell Mol Med; 2018 May; 22(5):2838-2845. PubMed ID: 29516641
[TBL] [Abstract][Full Text] [Related]
79. Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma.
Yeh CM; Chen PC; Hsieh HY; Jou YC; Lin CT; Tsai MH; Huang WY; Wang YT; Lin RI; Chen SS; Tung CL; Wu SF; Chang DC; Shen CH; Hsu CD; Chan MW
Oncotarget; 2015 Oct; 6(30):29555-72. PubMed ID: 26320192
[TBL] [Abstract][Full Text] [Related]
80. UBC
Ecke TH; Weiß S; Stephan C; Hallmann S; Barski D; Otto T; Gerullis H
Tumour Biol; 2017 May; 39(5):1010428317701624. PubMed ID: 28468590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
